We generated a new monoclonal antibody (MAb), F7.2.38, by immunizing mice with CD3 ␥␦ /CD3 complexes purified from human T-cells by OKT3 MAb-Sepharose affinity chromatography. Immunoprecipitation experiments and Western blotting analysis showed that MAb F7.2.38 recognized the CD3 chain in CD3 cDNA-transfected FOX B-cells and in various T-cell lines. Using flow cytometry on permeabilized or intact cells, the epitope was found to be located in the cytoplasmic tail of the CD3 chain. Immunohistochemical staining on paraffin-embedded sections showed that the reactivity of MAb F7.2.38 was comparable to that of the commercially available anti-CD3 polyclonal antibody. Of the 52 well-characterized T-cell lymphomas, 41 were positive for F7.2.38 (79%), whereas all 37 B-cell lymphomas and 69 non-lymphoid tumors were unreactive. This new anti-CD3 antibody would be particularly useful for phenotyping T-cell lymphomas on routinely processed paraffin-embedded tissue sections. (J Histochem Cytochem 48:
T he T-cell receptor is composed of two clonotypic chains, TCR ␣ and TCR ␤ , non-covalently associated with the invariant chains called CD3 ␥ , CD3 ␦ , CD3 , and (Clevers et al. 1988; Manolios et al. 1991; Rubin et al. 1994) . Monoclonal antibodies (MAbs) against the individual components of the TCR/CD3 complex have been useful tools in analyzing T-cell receptor complex structure and assembly. MAbs against TCR ␣ or TCR ␤ variable and constant regions, or external and cytoplasmic domains of CD3 chain, have been produced by immunizing mice, rats, or hamsters with human T-cell clones or lymphomas. The anti-CD3 MAbs are directed against two different types of epitopes: (a) unique "conformational epitopes" created in CD3 ␥ or CD3 ␦ heterodimers, and (b) epitopes on isolated CD3 chains (Pessano et al. 1985; Alarcon et al. 1991; Salmeron et al. 1991; San José et al. 1998 ). However, MAbs against the extracellular parts of CD3 ␥ or CD3 ␦ chains have never been ob-tained. This could be due either to amino acid sequence similarity between CD3 molecules of donor and recipient species or to lack of accessibility of the CD3 molecules to the immune system. However, there appear to be ample differences in amino acid sequences between CD3 ␥ and CD3 ␦ molecules from human and mouse (see Gold et al. 1987; Clevers et al. 1988; Salmeron et al. 1991) . Therefore, it may be that potential immunogenic epitopes on these molecules are not presented to antigen-recognizing T-and B-cells in the immunized animals, although why this should be is not clear.
These considerations have led us to develop methods for the production of MAbs against all components of known human TCR/CD3 complexes (pre-TCR, TCR ␥␦ , or TCR ␣␤ ). Such MAbs will be very useful for studies on TCR/CD3 structure and in the characterization of TCR complexes on T-lymphocytes in various diseases such as immunodeficiency, allergy, autoimmunity, and cancer. Our goal has been to produce MAbs useful in many different analytical systems, i.e., cytofluometry on living or permeabilized cells, immunohistochemistry on tissue sections prepared by different methods, immunoprecipitation in different detergents, and Western blotting analyses.
Because immunization with living T-cells has been unsuccessful, we attempted to isolate CD3 complexes from NP40-T cell lysates on anti-CD3 MAb affinity columns. Mice were injected with the eluted material, which contained mainly CD3 ␥ , ␦ , and molecules, plus an intracellular chaperone, CD3 , implicated in CD3 complex assembly (Pettey et al. 1987; Neisig et al. 1993 ).
Here we present the characterization of one of the MAbs obtained using this strategy. The MAb, F7.2.38, directed against a cytoplasmic epitope in the CD3 chain, recognizes an epitope present in both frozen and formalin-fixed material. The reactivity of this antibody was compared with that obtained using the commercially available rabbit anti-CD3 antibody (Dako; Trappes, France).
Materials and Methods
Production of MAb F7.2.38 CD3 complexes were obtained by affinity chromatography of 2% NP-40 detergent (Fluka Chemie; Buchs, Switzerland)solubilized proteins from Jurkat T-cells (250-500 ϫ 10 6 cells/immunization/mouse) on a 5-ml Sepharose bead column (Amersham Pharmacia Biotech; Orsay, France) with covalently coupled MAb OKT3. Elution was performed with 1 M NH 4 SCN or 0.2 M glycine buffer, pH 2.8. F1 hybrid female mice (C57B6 ϫ Balb/c) were immunized three times, once SC and twice IP, with eluted material in 250 l of DPBS (NaCl 0.14 M, Na 2 HPO 4 8 mM, KH 2 PO 4 1.5 mM, KCl 2.7 mM, pH 7.2) with 250 l of complete Freund's adjuvant (Statens Seruminstitut; Copenhagen, Denmark). Four months later the mice were immunized regularly (at least five times at 2-week intervals) with IP injections of equal doses of the CD3 complexes, still adsorbed onto the beads, without adding Freund's adjuvant. All mice produced antibodies precipitating CD3 ␥ , CD3 ␦ , CD3 , and CD3 proteins as well as molecules with higher ( Ͼ 30,000 Daltons) or lower ( Ͻ 20,000 Daltons) molecular weights (not shown). Five days after the last IP immunization, fusion of the spleen cells with the non-Ig-producing myeloma cell line X63 Ag8 653 was performed using standard techniques (Al Saati et al. 1989) . When hybridoma growth could be detected, supernatants were tested by cytofluorometry for the presence of MAbs that could recognize permeabilized Jurkat cells (see below). Supernatants from positive hybridomas were tested again in immunoprecipitation experiments with [ 35 S]-methionine/cysteine-labeled Jurkat cell lysates, as described in Geisler et al. (1990) . MAb F7.2.38 (of IgG 1 subclass) was selected for further detailed studies because it precipitated proteins with molecular weights similar to those of CD3 ␥ , CD3 ␦ , CD3 , and CD3 chains.
Cell lines and MAbs
Human leukemia ␣␤ (Jurkat subclone E6.1, HBP-ALL, CEM, and MOLT4) and ␥␦ (LYON and PEER) T-cells, human B-lymphoma Raji cells, and murine B-lymphoma FOX cells were grown in RPMI 1640 with l -Glutamate supple-mented with 1 mM sodium pyruvate, penicillin/neomycin/ streptomycin mixture (Life Technology; Eragny, France), and 8% of fetal calf serum (FCS) (Roche; Meylan, France).
Mouse SP-34, OKT3, and F101.01 MAbs specific for single or CD3-associated CD3 components, respectively, were obtained from Dr. C. Terhorst (Boston, MA), ATCC (Rockville, MD), and Dr. T. Plesner (Copenhagen, Denmark). CD20/L26 anti-B cell MAb and the rabbit polyclonal anti-CD3 (A0452) were purchased from Dako.
Flow Cytometric Analyses
Cells were permeabilized using 0.1% saponin (Sigma; Saint Quentin Fallavier, France). A total of 10 6 cells were washed in DPBS and labeled for 30 min at 4C with F7.2.38, SP-34, and OKT3 MAbs supplemented with 0.1% saponin. After two washes in DPBS containing 0.1% saponin, cells were incubated for 30 min at 4C with a fluorescein isothiocyanateconjugated rabbit Fab 2 Ј anti-mouse (F0313; Dako) supplemented with 0.1% saponin. Cells were washed in DPBS with 0.1% saponin and analyzed with the Coulter Electronics Cytometer (Coulter EPICS XL; Hialeah, FL).
For surface staining analysis, exactly the same procedure was followed, but without adding saponin, and using a phycoerythrin-conjugated goat anti-mouse (IM0551; Immunotech, Marseille, France) as secondary antibody.
Transfections
Murine B-lymphoma FOX cells were transfected by electroporation. Approximately 5 ϫ 10 6 cells were washed twice in culture medium without FCS, resuspended in the DNA transfection mixture [5 g of pSRa-CD3 del12 described by B. Alarcon (Mallabiabarrena et al. 1992 ), linearized by digestion with BamH1, precipitated, and resuspended in 750 l of the cell culture medium without FCS] and then electroporated in 0.4-cm cuvettes (Ozyme; Montigny, France) at 270 V, 960 F using a Biorad Gene Pulser apparatus (Bio-Rad; Ivry Sur Seine, France). The cells were carefully resuspended in a 25-cm 2 flask containing 10 ml of culture medium. At 48 hr later, 2 mg/ml of G418 (Life Technologies) was added to the medium. When viable cells began to appear (approximately 10 days later), clonings by limiting dilutions were made in the presence of 1 mg/ml of G418. The positive clones were selected by flow cytometry using 0.1% saponin and the anti-CD3 MAb SP-34. In this report, all results shown were obtained with clone T116.4.3.
Western Blotting Experiments
A total of 5 ϫ 10 6 FOX, T116.4.3, or Jurkat E6.1 cells were washed twice in DPBS and then lysed in 500 l of Tris 0.5 M, pH 6.8, 2% SDS, 10% glycerol, bromophenol blue, with or without 5% ␤ -mercaptoethanol. After three 5-sec sonications, lysates were boiled for 10 min at 100C and centrifuged for 10 min at 14000 ϫ g, 4C. Thirty l of supernatant was separated by SDS-PAGE (12%) according to the Laemmli (1970) . Electrophoresis was followed by transfer of proteins to PVDF membranes (NEN Life Science Products; Paris, France) at 4C, 190 mA, 3 hr. At the end of the electrotransfer, membranes were colored with Ponceau's red to control the quality of the transfer and the loaded samples. Then they were incubated for 1 hr, first with blocking buffer [DPBS; 0.1% Tween-20 (Merck; Fontenay, France), 0.1% gelatin, 5% skimmed milk, and 0.5 g/liter BSA], second with blocking buffer diluted twice and containing SP-34 or F7.2.38 MAb supernatant diluted 10 times. Then membranes were washed three times for 5 min in DPBS with 0.1% Tween-20, and bound antibodies were detected with HRP-conjugated rabbit anti-mouse Ig (P0161; Dako). Peroxidase activity was revealed using an Enhanced Chemiluminescence Detection system (Amersham Pharmacia Biotech).
Immunostaining of Various Human Normal and Neoplastic Tissue Sections
F7.2.38 supernatant diluted 1:10 was used to study its reactivity on a large panel of a variety of normal and pathological human tissue samples from the tissue bank of the department of Pathology at Purpan Hospital in Toulouse, using the multi-tissue block method (Battifora 1986 ). Tissue samples were fixed in 10% neutral buffered formalin or Duboscq-Brasil (ethanol-based Bouin's fluid), and in a few cases in Bouin's fixative, Bouin Holland, and B5, to assess the fixative dependence of the staining intensity.
Different human tumors ( n ϭ 179) were investigated. These included: (a) 110 cases of lymphoid neoplasms [including 89 non-Hodgkin's lymphomas classified according to the REAL and the WHO classifications (Harris et al. 1994 (Harris et al. , 2000 and 21 cases of Hodgkin's disease (Table 1) ];
and (b) 69 cases of non-lymphoid tumors of different categories. In addition, 142 cases of normal or non-neoplastic lymphoid ( n ϭ 28) and non-lymphoid ( n ϭ 114) tissue samples were investigated to evaluate the reactivity of this antibody in normal human organ tissue specimens.
Paraffin-embedded sections were immunostained by the streptavidin-biotin-peroxidase complex (ABC) method using Dako StrepABComplex/HRP Duet (mouse/rabbit) kit (K0492; Dako). The antigen retrieval method used heat pretreatment of sections in a 750-W microwave oven (10 min of boiling twice in citrate buffer, pH 6) (Shi et al. 1991) . In some cases, we also evaluated the immunostaining on paraffin-embedded tissue sections using this antibody with two different immunostains: Techmate 500 (Dako) and Ventana 320/ES (Ventana; Strasbourg, France). MAbs. MAb F7.2.38 was selected because it could (a) recognize the human leukemia T-cell line Jurkat by intracellular staining analyzed by flow cytometry and (b) immunoprecipitate proteins with molecular weights similar to those of the CD3 ␥ , CD3 ␦ , CD3 , and CD3 chains from 2% NP-40 lysates of Jurkat cells. All TCR/CD3 proteins except CD3 are usually co-precipitated with an anti-CD3 MAb from a 1% digitonin T-cell lysate. However, if 2% NP-40 is used, only CD3 ␥ , ␦ , , and chains are co-precipitated. Therefore, comparable immunoprecipitations with MAb F7.2.38 of either digitonin or NP-40 lysates may indicate whether the MAb is specific for CD3 ␥␦ or CD3 molecules. The results in Figure 1 demonstrate that MAb F7.2.38, like MAb OKT3, co-precipitated three bands corresponding to CD3␥␦ and CD3 from NP-40 lysates and no CD3 molecules from digitonin lysates. Consequently, MAb F7.2.38 appeared to react against the CD3␥␦ chains rather than CD3. One difference between the immunoprecipitations with MAbs OKT3 and F7.2.38 was the presence of an additional band of 40 kD in the F7.2.38 immunoprecipitates (arrow). This 40,000-Dalton band was also present in immunoprecipitates with the SP-34 MAb specific for single CD3 chains (data not shown). The same results were obtained when we used MAb F7.2.38 with lysates from other human T-cell lines, such as the ␣␤ HBP-ALL, CEM, and MOLT4 T-cell lines or the ␥␦ LYON and PEER T-cell lines (data not shown). MAb F7.2.38 did not immunoprecipitate any TCR/CD3like proteins from Raji B-cell lysates (Figure 1) . These data indicate that MAb F7.2.38 reacts similarly to some other anti-CD3 MAbs in both detergents used.
Results

Characterization of the Molecule Targeted by MAb F7.2.38
Similar Patterns of Proteins Precipitated by Known
MAb F7.2.38 Specifically Recognizes the Human CD3 Chain. These results led us to postulate that MAb F7.2.38 could be directed against the CD3 (Harris et al. 1994 (Harris et al. ,2000 Non-Hodgkin's Lymphomas (89 cases Figure 3 shows that a ‫-04ف‬kD band was revealed by MAb F7.2.38 in T116.4.3 cell lysates but not in FOX cell lysates. The proteins in this band were reduced (in the presence of ␤-mercaptoethanol) to a ‫-02ف‬kD band, indicating that the 40-kD band represented a disulfide-linked homodimer of CD3 chains. In E6.1 cell lysates, MAb F7.2.38 revealed a 20-kD band and a 40-kD band. As before, the 40-kD molecules (but not the 20-kD molecules) were reduced to 20 kD. This 40-kD band appears similar to a corresponding molecule in Figure 1 (arrow Figure 3 ). However, cell surface staining was detected on T116.4.3 and E6.1 cells with MAb SP-34 but not with MAb F7.2.38 ( Figure 2B ). Therefore, unlike MAb SP-34, this MAb is most likely directed against the cytoplasmic region of the CD3 chain.
Reactivity of MAb F7.2.38 on Paraffin-embedded Tissue Sections
Normal Human Tissues. In normal lymphoid tissue, MAb F7.2.38 showed strong staining of lymphoid cells in the medulla and cortex of normal thymus ( Figure  4A ). As expected, only scattered B-lymphocytes in the cortex and medulla were labeled with MAb CD20/ L26 ( Figure 4B ). In human lymph node and tonsil, interfollicular areas containing the T-lymphocytes were strongly stained, well delimiting B-cell follicles in which some small reactive T-cells were labeled ( Figure  4C ). This reactivity was complementary with immunostaining of B-cell zones using MAb CD20/L26 in lymph node tissue ( Figure 4D ). With the exception of scattered T-cells, MAb F7.2.38 was unreactive with all other normal human tissues studied (data not shown).
Immunostaining on frozen and paraffin-embedded tissue sections was comparable, and therefore only paraffin sections were used in further experiments. Almost all results obtained with MAb F7.2.38 were comparable to the reference antibody, the rabbit polyclonal anti-CD3 antibody.
Neoplastic Human Tissues
Lymphoid Tumors. The reactivity of MAb F7.2.38 with lymphoid tumors is shown in Table 1 . All B-cell lymphomas were negative for F7.2.38 (0 ϩ /37), and only small reactive T-cells were strongly positive with this antibody. On the contrary, the majority of T-cell lymphomas [41 ϩ /52 (79%)] were positive for MAb F7.2.38 ( Figures 4E-4H ). As expected, anaplastic large-cell lymphomas (ALCLs) showed a lower rate of immunostaining with this antibody [6 ϩ /14 (43%)] in comparison with the other types of T-cell lymphomas [35 ϩ /38 (92%)] (Table 1) ( Figures 4E-4G ). In this group of T-cell lymphomas, only 6/14 cases studied showed a positive staining of a variable percentage of neoplastic cells for F7.2.38. The labeling intensity was also variable from case to case and overall was lower than that obtained in the other types of T-cell lymphomas. It is noteworthy that in 2/6 positive ALCLs, only rare neoplastic cells showed weak cytoplasmic staining with MAb F7.2.38. Of note was the reactivity of MAb F7.2.38 with nasal type extranodal NK/T-cell lymphoma. In this last category, 3/5 cases studied were positive for MAb F7.2.38 (Table 1) and virtually all neoplastic cells were labeled (data not shown). Lastly, among the 21 cases of Hodgkin's disease of different categories, only two cases (9.5%) showed focal cytoplasmic staining of a variable number of Hodgkin and Reed-Sternberg cells. In the other cases, neoplastic cells were clearly negative and were often surrounded by strongly labeled small T-lymphocytes.
Non-lymphoid Tumors. The 69 non-lymphoid tumors investigated were always negative for MAb F7.2.38, which stained only small reactive T-cells (data not shown). The same results were obtained with the polyclonal anti-CD3 antibody. The F7.2.38 antibody worked well on paraffin sections stained either manually, or with either of two automated immunostainers (TechMate 500 and Ventana 320/ES).
Discussion
In this article we have described a novel MAb, F7.2.38, which recognizes the human CD3 chain, associated or not with the TCR/CD3 complex. This MAb can be used for all biochemical and immunohistochemical methods in T-cell receptor research and in routine clinical laboratory tests. Our results show that MAb F7.2.38 recognizes both monomeric and dimeric forms of the CD3 chain (see Figure 3 ). The latter form is dominant in the CD3 cDNA-transfected non-T-cells compared to normal T-lymphocytes, in which all components of the TCR/CD3 complex are present. These results are in agreement with those described by others (Pessano et al. 1985; Alarcon et al. 1991; Salmeron et al. 1991; Huppa and Ploegh 1997) .
The main result from this study is that MAb F7.2.38 is directed against a fixative-resistant epitope of the CD3 polypeptide. Therefore, it can be used to identify normal and neoplastic T-cells on paraffinembedded tissue sections. The reactivity of the polyclonal anti-CD3 antibody on routinely processed biopsy specimen made it a valuable reagent for identification of T-cell lymphoid malignancies. The reactivity of MAb F7.2.38 was very similar to that of the routinely used polyclonal anti-CD3 antiserum. It is of interest that almost all T-cell neoplasms other than anaplastic large-cell lymphoma express CD3 antigen on the surface and/or in the cytoplasm, whereas B-cell lymphomas are invariably negative. As previously reported (Benharroch et al. 1998) , ALCLs are positive for anti-CD3 antibody in approximately one third of cases. In addition, in this group of T-cell lymphomas the staining intensity and the percentage of positive cells are always lower than those observed in the other T-cell lymphoma subtypes. It is also of interest to note the cytoplasmic staining of three out of the five nasal type extranodal NK/T-cell lymphoma cases. As previously reported (Jaffe et al. 1996) , in this category of T-cell lymphomas cytoplasmic CD3 is often detected using polyclonal antiserum to CD3 in paraffin sections despite the lack of CD3 detection on the cell membrane. This latter finding is likely consistent with the cytoplasmic expression of CD3 chain by the majority of NKcells, from which these lymphomas originate (Lanier et al. 1992 ). Finally, in Hodgkin's disease, which is now considered to be a neoplasm of B-cell origin (Kanzler et al. 1996) , the CD3 reactivity of Reed-Sternberg cells in some cases appears as a globular and not as a diffuse cytoplasmic staining, as previously reported (Cibull et al. 1989; Al Saati et al. 1997) .
Until now, the polyclonal anti-CD3 has been the most commonly used antibody in immunohistochemistry on paraffin sections, giving specific and intense staining of reactive and neoplastic T-cells ). It should be noted that, except for MAb F7.2.38, none of the available MAbs directed against the CD3 chain is suitable for use on routinely fixed and paraffin-embedded tissues. This is probably due to the fact that the vast majority of these MAbs (see Salmeron et al. 1991) are directed against conformational epitopes, especially in the extracellular domain of the CD3 chain, which could be easily destroyed by fixation of tissues. Interestingly, both the polyclonal anti-CD3 and the F7.2.38 mAb appear to recognize the cytoplasmic region of the CD3. This unique reactivity provides a valuable tool for functional and immunohistochemical studies. In the present study, we noted that MAb F7.2.38 worked as well as the polyclonal anti-CD3 in immunohistochemical methods, either manually or using automated immunostainers.
In summary, we have produced a novel MAb directed against the human CD3 protein, which would be very useful in studies on TCR/CD3 complex assembly as well as in the immunohistochemical diagnosis of T-cell lymphomas. 
